Deutsche Bank AG reaffirmed their hold rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note issued to investors on Tuesday, July 25th, MarketBeat reports. They currently have a GBX 1,720 ($22.33) target price on the stock.
Several other equities analysts have also recently weighed in on GSK. UBS AG set a GBX 1,600 ($20.77) target price on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research note on Thursday, April 27th. Shore Capital reissued a hold rating on shares of GlaxoSmithKline plc in a research note on Thursday, March 30th. BNP Paribas reissued an underperform rating and issued a GBX 1,520 ($19.73) target price on shares of GlaxoSmithKline plc in a research note on Monday, April 3rd. Morgan Stanley set a GBX 1,700 ($22.07) price target on GlaxoSmithKline plc and gave the company a neutral rating in a report on Monday, May 29th. Finally, Liberum Capital reaffirmed a buy rating and set a GBX 1,900 ($24.67) price target on shares of GlaxoSmithKline plc in a report on Wednesday, May 31st. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of GBX 1,724 ($22.38).
Shares of GlaxoSmithKline plc (LON GSK) traded down 1.06% during trading on Tuesday, hitting GBX 1490.00. 7,080,333 shares of the company were exchanged. GlaxoSmithKline plc has a 12 month low of GBX 1,446.50 and a 12 month high of GBX 1,745.56. The stock’s market cap is GBX 72.83 billion. The company’s 50-day moving average price is GBX 1,564.93 and its 200 day moving average price is GBX 1,621.93.
ILLEGAL ACTIVITY WARNING: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2017/08/19/deutsche-bank-ag-reiterates-hold-rating-for-glaxosmithkline-plc-longsk-updated-updated-updated.html.
The company also recently declared a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be issued a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.
In other news, insider Patrick Vallance purchased 861 shares of GlaxoSmithKline plc stock in a transaction dated Friday, July 14th. The shares were bought at an average cost of GBX 1,618 ($21.00) per share, for a total transaction of £13,930.98 ($18,085.14). Also, insider Victoria Whyte sold 4,820 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($21.98), for a total value of £81,602.60 ($105,936.13). Over the last 90 days, insiders have bought 3,151 shares of company stock worth $5,054,922.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.
